UPDATE: JP Morgan Initiates Overweight on ZIOPHARM Oncology; Standard Bearing Asset

JP Morgan initiates its coverage on ZIOPHARM Oncology ZIOP with a rating of Overweight and a price target of $7. JP Morgan notes, "We are initiating coverage of ZIOP with an OW rating and a YE12 target of $7. Lead asset, palifosfamide (pali), is in Phase 3 (PICASSO 3) for soft tissue sarcoma (STS). If data is positive, we expect pali to become the new standard of care front line therapy. Top-line data are expected in 2H12, and we assign a 65% probability of success. Small cell lung cancer represents a compelling, albeit higher risk, second shot on goal." ZIOP closed at $4.39 on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetInitiationAnalyst RatingsJP Morgan
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!